LOS ANGELES--(BUSINESS WIRE)--Avantogen Oncology, Inc. (OTCBB:AVTO) today announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug Application (IND) for RP101, a compound being investigated for the treatment of patients with pancreatic cancer.
